Incyte stock: Company halts planned Phase 3 ovarian study
Published on 11/19/2026 at 02:33 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSPipeline decision and investor implications
- Incyte will not start the planned MAESTRA-3 trial of INCB123667 with bevacizumab in first-line ovarian cancer maintenance therapy.
- The company said the decision is not expected to change its financial guidance or previously disclosed long-term outlook.
Incyte said on November 13, 2026, that it would not proceed with the planned Phase 3 MAESTRA-3 study in ovarian cancer. The company disclosed the decision in a SEC filing.
Pipeline Priority Reshapes Ovarian Program
MAESTRA-3 was designed to evaluate INCB123667, Incyte's selective CDK2 inhibitor, in combination with bevacizumab as first-line maintenance therapy for patients with ovarian cancer. The study had been expected to begin in the fourth quarter of 2026.
Incyte said the decision followed prioritization of its clinical development portfolio. It was not based on safety or efficacy findings from the INCB123667 program, and the company does not expect the move to affect its financial guidance or previously disclosed long-term outlook.
Business Focus and Competitive Context
Incyte is a Delaware biopharmaceutical company developing medicines through clinical programs. Its portfolio includes INCB123667, a selective CDK2 inhibitor being studied in oncology. The company is headquartered in Wilmington, Delaware.
Incyte company facts
- Company: Incyte Corporation
- ISIN: US45337C1027
- Ticker: INCY
- Primary exchange: The Nasdaq Stock Market LLC
The broader US market environment is tracked through the S&P 500.
